NASDAQ:UTHR United Therapeutics (UTHR) Stock Price, News & Analysis $541.89 +60.42 (+12.55%) Closing price 04:00 PM EasternExtended Trading$543.45 +1.56 (+0.29%) As of 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About United Therapeutics Stock (NASDAQ:UTHR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get United Therapeutics alerts:Sign Up Key Stats Today's Range$475.46▼$557.3750-Day Range$472.21▼$538.8452-Week Range$409.07▼$609.35Volume3.30 million shsAverage Volume532,012 shsMarket Capitalization$23.24 billionP/E Ratio19.39Dividend YieldN/APrice Target$621.00Consensus RatingModerate Buy Company Overview United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company’s products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment. United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets. Its medicines are used to help improve exercise capacity and delay disease progression in patients with PAH, a chronic condition involving high blood pressure in the arteries of the lungs. In addition to its pharmaceutical business, the company is pursuing technologies intended to address the shortage of transplantable organs. Its research activities include the development of genetically engineered organs from pigs, lung regeneration and preservation, and three-dimensional bioprinting. United Therapeutics was founded in 1996 by Martine Rothblatt, who serves as chairperson and chief executive officer.AI Generated. May Contain Errors. Read More United Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScoreUTHR MarketRank™: United Therapeutics scored higher than 75% of companies evaluated by MarketBeat, and ranked 150th out of 891 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingUnited Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 11 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialUnited Therapeutics has a consensus price target of $621.00, representing about 14.4% upside from its current price of $542.77.Amount of Analyst CoverageUnited Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about United Therapeutics' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth13.16% Earnings GrowthEarnings for United Therapeutics are expected to grow by 13.16% in the coming year, from $26.21 to $29.66 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of United Therapeutics is 19.46, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.79.Price to Earnings Ratio vs. SectorThe P/E ratio of United Therapeutics is 19.46, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.07.Price to Earnings Growth RatioUnited Therapeutics has a PEG Ratio of 2.43. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioUnited Therapeutics has a P/B Ratio of 3.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about United Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.14% of the float of United Therapeutics has been sold short.Short Interest Ratio / Days to CoverUnited Therapeutics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in United Therapeutics has recently increased by 35.97%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldUnited Therapeutics does not currently pay a dividend.Dividend GrowthUnited Therapeutics does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.58 News SentimentUnited Therapeutics has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 30 news articles for United Therapeutics this week, compared to 10 articles on an average week.Search Interest7 people have searched for UTHR on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added United Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, United Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $188,089,856.00 in company stock.Percentage Held by Insiders8.60% of the stock of United Therapeutics is held by insiders.Percentage Held by Institutions94.08% of the stock of United Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about United Therapeutics' insider trading history. Receive UTHR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. UTHR Stock News HeadlinesLiquidia slumps after US court rules for United Therapeutics in patent fight2 hours ago | reuters.comCritical Comparison: United Therapeutics (NASDAQ:UTHR) and Humacyte (NASDAQ:HUMA)September 30 at 5:48 AM | americanbankingnews.comThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company the same size Nvidia was a decade ago. Brown says this firm's patented technology can produce intelligence up to 1,000 times faster than standard AI, and he expects Elon Musk to fuel demand starting November 11. The technology is protected by 150 patents.September 30 at 1:00 AM | Brownstone Research (Ad)United Therapeutics CEO sold 9,500 shares under planSeptember 30 at 4:02 AM | americanbankingnews.comInsider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 SharesSeptember 22, 2026 | insidertrades.comUnited Therapeutics (NASDAQ:UTHR) EVP Sells $4,129,582.00 in StockSeptember 19, 2026 | insidertrades.comUnited Therapeutics (NASDAQ:UTHR) CEO Sells $4,763,205.00 in StockSeptember 18, 2026 | insidertrades.comInsider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of StockSeptember 10, 2026 | insidertrades.comSee More Headlines UTHR Stock Analysis - Frequently Asked Questions How have UTHR shares performed this year? United Therapeutics' stock was trading at $487.25 at the beginning of 2026. Since then, UTHR stock has increased by 11.4% and is now trading at $542.77. How were United Therapeutics' earnings last quarter? United Therapeutics Corporation (NASDAQ:UTHR) released its earnings results on Wednesday, August, 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.86 by $0.41. The company's revenue for the quarter was down 1.9% on a year-over-year basis. Read the conference call transcript. How do I buy shares of United Therapeutics? Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of United Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that United Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW). Company Calendar Last Earnings8/05/2026Today9/30/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 UTHR's financial health is in the Yellow zone, according to TradeSmith. UTHR has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:UTHR CIK1082554 Webwww.unither.com Phone(301) 608-9292Fax301-608-9291Employees1,400Year Founded1996Price Target and Rating Average Price Target for United Therapeutics$621.00 High Price Target$735.00 Low Price Target$321.00 Potential Upside/Downside+14.6%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)$27.95 Trailing P/E Ratio19.39 Forward P/E Ratio20.67 P/E Growth2.43Net Income$1.33 billion Net Margins41.56% Pretax Margin49.87% Return on Equity20.18% Return on Assets17.98% Debt Debt-to-Equity RatioN/A Current Ratio5.73 Quick Ratio5.41 Sales & Book Value Annual Sales$3.18 billion Price / Sales7.30 Cash Flow$36.81 per share Price / Cash Flow14.72 Book Value$164.81 per share Price / Book3.29Miscellaneous Outstanding Shares42,890,000Free Float39,202,000Market Cap$23.24 billion OptionableOptionable Beta0.56 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:UTHR) was last updated on 9/30/2026 by MarketBeat.com Staff. From Our PartnersTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredLegendary U.S. Congressman Issues WarningDr. Ron Paul warns a dangerous experiment is already underway in Washington, involving at least 27 billion dol...Altimetry | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredI've seen this movie before (last time: 17,556%)My track record speaks for itself... KDA: 17,556%. PRE: 3,900%. OCEAN: 2,650%. Every single one was called ...Crypto 101 Media | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding United Therapeutics Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share United Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
